First-line immunotherapy in non-small cell lung cancer: how to select and where to go-Reference-Cited by-同舟云学术

First-line immunotherapy in non-small cell lung cancer: how to select and where to go

Published:2023-12-02 Issue:12 Volume:17 Page:1191-1206
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Mogavero Andrea¹,Cantale Ornella¹^ORCID,Mollica Veronica²,Anpalakhan Shobana³,Addeo Alfredo⁴,Mountzios Giannis⁵,Friedlaender Alex⁶,Kanesvaran Ravindran⁷⁸,Novello Silvia¹,Banna Giuseppe Luigi³⁹

Affiliation:

1. Department of Oncology, University of Turin, Turin, Italy

2. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

3. Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK

4. Oncology Department, HUG-Hopitaux Universitaires de Geneve, Geneva, Switzerland

5. Fourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece

6. Oncology Department, University Hospital, Geneva, Switzerland

7. Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore

8. SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore, Singapore

9. Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK

Funder

funding

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17476348.2024.2302356

Reference133 articles.

1. Lung cancer

2. Harnessing the immune system to improve cancer therapy

3. Active and passive immunization for cancer

4. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

5. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations